AU2008228303B2 - Substituted pyrimidodiazepines useful as PLK1 inhibitors - Google Patents

Substituted pyrimidodiazepines useful as PLK1 inhibitors Download PDF

Info

Publication number
AU2008228303B2
AU2008228303B2 AU2008228303A AU2008228303A AU2008228303B2 AU 2008228303 B2 AU2008228303 B2 AU 2008228303B2 AU 2008228303 A AU2008228303 A AU 2008228303A AU 2008228303 A AU2008228303 A AU 2008228303A AU 2008228303 B2 AU2008228303 B2 AU 2008228303B2
Authority
AU
Australia
Prior art keywords
methyl
mole
tetrahydro
pyrimido
diazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008228303A
Other languages
English (en)
Other versions
AU2008228303A1 (en
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008228303(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2008228303A1 publication Critical patent/AU2008228303A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: F. HOFFMANN-LA ROCHE AG
Application granted granted Critical
Publication of AU2008228303B2 publication Critical patent/AU2008228303B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU2008228303A 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as PLK1 inhibitors Ceased AU2008228303B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
US60/919,358 2007-03-22
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (2)

Publication Number Publication Date
AU2008228303A1 AU2008228303A1 (en) 2008-09-25
AU2008228303B2 true AU2008228303B2 (en) 2012-04-19

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008228303A Ceased AU2008228303B2 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as PLK1 inhibitors

Country Status (23)

Country Link
US (1) US7517873B2 (cg-RX-API-DMAC10.html)
EP (1) EP2139892B1 (cg-RX-API-DMAC10.html)
JP (1) JP5087640B2 (cg-RX-API-DMAC10.html)
KR (1) KR101157848B1 (cg-RX-API-DMAC10.html)
CN (2) CN101636399B (cg-RX-API-DMAC10.html)
AR (1) AR065794A1 (cg-RX-API-DMAC10.html)
AT (1) ATE524472T1 (cg-RX-API-DMAC10.html)
AU (1) AU2008228303B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0809088A2 (cg-RX-API-DMAC10.html)
CA (1) CA2680757A1 (cg-RX-API-DMAC10.html)
CL (1) CL2008000785A1 (cg-RX-API-DMAC10.html)
CY (1) CY1112102T1 (cg-RX-API-DMAC10.html)
DK (1) DK2139892T3 (cg-RX-API-DMAC10.html)
ES (1) ES2371832T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20110807T1 (cg-RX-API-DMAC10.html)
IL (1) IL200617A (cg-RX-API-DMAC10.html)
MX (1) MX2009010034A (cg-RX-API-DMAC10.html)
PE (1) PE20120495A1 (cg-RX-API-DMAC10.html)
PL (1) PL2139892T3 (cg-RX-API-DMAC10.html)
PT (1) PT2139892E (cg-RX-API-DMAC10.html)
SI (1) SI2139892T1 (cg-RX-API-DMAC10.html)
TW (1) TWI363629B (cg-RX-API-DMAC10.html)
WO (1) WO2008113711A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008287339A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
BRPI0817315A2 (pt) * 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
CN101878216B (zh) * 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
WO2011031965A1 (en) 2009-09-14 2011-03-17 Gilead Sciences, Inc. Modulators of toll-like receptors
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2970317A4 (en) 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
HUE038820T2 (hu) 2013-11-13 2018-11-28 Vertex Pharma Eljárás influenzavírusok replikációjának inhibitorai elõállítására
EP3099693A4 (en) * 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
CN107074860B (zh) 2014-09-16 2022-07-15 吉利德科学公司 制备toll样受体调节剂的方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
AU2017248186B2 (en) * 2016-04-07 2021-10-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020356484A1 (en) 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
JP7555155B2 (ja) * 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規plk1分解誘導化合物
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1053831A1 (zh) * 1999-09-17 2003-11-07 Basf Aktiengesellschaft 作为治疗药物的激酶抑制剂
UY27427A1 (es) 2001-09-04 2003-03-31 Boehringer Ingelheim Pharma Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
ATE479434T1 (de) * 2006-02-14 2010-09-15 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
CN102746175A (zh) 2012-10-24
AR065794A1 (es) 2009-07-01
HK1139936A1 (en) 2010-09-30
IL200617A (en) 2014-02-27
US7517873B2 (en) 2009-04-14
CL2008000785A1 (es) 2009-03-27
CA2680757A1 (en) 2008-09-25
TW200843781A (en) 2008-11-16
KR101157848B1 (ko) 2012-07-11
MX2009010034A (es) 2009-10-12
EP2139892A1 (en) 2010-01-06
HRP20110807T1 (hr) 2011-12-31
PE20120495A1 (es) 2012-05-12
PL2139892T3 (pl) 2012-03-30
BRPI0809088A2 (pt) 2014-09-09
TWI363629B (en) 2012-05-11
CN101636399B (zh) 2012-04-18
ATE524472T1 (de) 2011-09-15
EP2139892B1 (en) 2011-09-14
JP5087640B2 (ja) 2012-12-05
WO2008113711A1 (en) 2008-09-25
AU2008228303A1 (en) 2008-09-25
PT2139892E (pt) 2011-11-21
CN101636399A (zh) 2010-01-27
JP2010521514A (ja) 2010-06-24
KR20090119913A (ko) 2009-11-20
US20080234255A1 (en) 2008-09-25
SI2139892T1 (sl) 2011-12-30
CN102746175B (zh) 2014-01-15
DK2139892T3 (da) 2011-12-12
CY1112102T1 (el) 2015-11-04
IL200617A0 (en) 2010-05-17
ES2371832T3 (es) 2012-01-10

Similar Documents

Publication Publication Date Title
AU2008228303A1 (en) Substituted pyrimidodiazepines useful as PLK1 inhibitors
TWI534145B (zh) 四氫吡啶并嘧啶衍生物
CN114555593A (zh) 作为parg抑制剂的4-取代的吲哚和吲唑磺酰胺衍生物
AU2018285131B2 (en) Heteroaromatic compounds as Vanin inhibitors
US11230551B2 (en) Deuterated analogs of MK2 inhibitors and uses thereof
JP2022517410A (ja) イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
EP3768272B1 (en) Jak inhibitors
EP2112150A1 (en) Improved raf inhibitors
AU2009294660A1 (en) New compounds I
US20170105994A1 (en) Certain protein kinase inhibitors
KR20240130693A (ko) Cdk9 억제제 및 이의 용도
US20190359618A1 (en) Compounds for inhibiting lrrk2 kinase activity
AU2021410926A9 (en) Tetrahydrothienopyrimidinesulfonamide compounds
TWI875911B (zh) Bruton酪胺酸激酶(BTK)抑制劑
AU2021270672A1 (en) Fused aza-heterocyclic amide compound and use thereof
CN121487932A (zh) 一种内酰胺结构cdk抑制剂化合物
CN121494858A (zh) N-(1h-吡唑-3-基)杂环胺类衍生物及其制备方法和用途
MX2010011136A (es) Derivados de pirrolo [2,3-d] pirimidin-2-il-amina como inhibidores pkc-theta.
HK1139936B (en) Substituted pyrimidodiazepines useful as plk1 inhibitors
HK1218119B (en) Certain protein kinase inhibitors
HK1219071B (en) New compounds
HK1219071A1 (en) New compound

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): F. HOFFMANN-LA ROCHE AG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired